Dr. Moshe Lapidot, MD

About Dr. Lapidot

Thoracic surgeon Dr. Moshe Lapidot serves as director of the Thoracic Surgery Unit at Galilee Medical Center. His clinical and research work focuses on thoracic cancers, including pleural mesothelioma. In 2026, Lapidot was elected to the American Association for Thoracic Surgery.

His research has explored new treatment approaches for mesothelioma. In 2021, Dr. Lapidot and his research team published their work on a potential new mesothelioma immunotherapy target called STAT3. His research has also explored heparanase inhibitors as a potential treatment approach.

“I believe there is still much to learn about how mesothelioma grows and develops in the body,” Lapidot said. “But every day provides hope that a new piece of information will eventually lead to a cure.”

“This target for mesothelioma immunotherapy has great potential,” he said. “Our data from this study suggested that STAT3 inhibitors could play a vital role combined with immune checkpoint inhibitors or chemotherapy.”

“The results strongly encourage further testing, and I’m optimistic that these therapies could become a new standard one day,” Lapidot said of the research involving heparanase inhibitors.

Lapidot graduated from Technion-Israel Institute of Technology in 2006 with his doctorate in medicine. He later completed his thoracic surgery fellowship at Harvard Medical School in 2018. He served as an associate surgeon at Brigham and Women’s Hospital in Boston and as a surgical instructor at Harvard Medical School.

Dr. Lapidot’s Role as Medical Reviewer on Asbestos.com

Dr. Lapidot has contributed his experience in thoracic surgery and mesothelioma research to the medical review of information on Asbestos.com. His clinical and research background has helped ensure that content meets high medical and scientific standards for accuracy regarding mesothelioma and other asbestos-related diseases.